Menu

Markets

Research

News

Learn
Paper trading
AI Chat
WatchlistsPortfoliosAlerts
Sign in

Vaccinex, Inc. VCNX

Set alert

Price alert · VCNX

All alert types
0.75 USD 0.00 0.00%

At close · Oct 29

0.72605 Day range 0.72605
0.34 52-week range 1.49
YTD
-30.56%
1 year
+10.29%
Open
0.72605
Prev close
0.75
Mkt cap
2.01M
Vol
2
Avg vol
1.20K
EPS
-6.53
P/E
0.00
Div yield
0.00%
More statistics
Low
0.72605
High
0.72605
Forward P/E
-9.36
Beta
0.00
Short ratio
0.60
Inst. own
51.30%
Dividend
0.00
Ex-div date
Earnings
Nov 14, 2024
50-d avg
3.19
200-d avg
5.21
1y target
0.00

5D chart

Chart tools
Interval
1m5m15m30m

Chart is warming up

The five-day price history for VCNX has not been loaded yet. Try again in a moment.

Discussion (119)

Sign in to join the discussion

VICKY HANUKA VCNX 2 years ago #2

Vaccinex Inc Announces Reverse Stock Split and Equity Adjustments
Vaccinex Inc Announces Reverse Stock Split and Equity Adjustments
Vaccinex Inc (VCNX) has released an update.

On February 14, 2024, Vaccinex, Inc. implemented a 1-for-14 reverse stock split, consolidating every fourteen shares into one. This adjustment, effective on February 19, aims to maintain proportional shareholder interests, adjusting equity incentive plans accordingly, without changing stock par value or shareholders’ voting rights. The stock will trade under the same symbol “VCNX” with a new CUSIP number starting February 20 on Nasdaq. Despite these changes, the company cautions that forward-looking statements involve risks and actual results may vary.

For further insights into VCNX stock, check out TipRanks’ Stock Analysis page.

VICKY HANUKA VCNX 3 years ago #5

?????????????? Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi

-- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.